Consequently, the activation of the STAT5A/miR-202-5p/USP15/Caspase-6 signaling pathway can lead to imatinib resistance and ameliorate apoptosis in CML cells [47] (Fig. 2C). The gene discussed is STAT5A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.